SUMMARYLaboratory bioassays were conducted to evaluate the effects of spiromesifen on the fecundity, fertility and population growth of two-spotted spider mite (Tetranychus urticae Koch) after treatment of pre-ovipositing females with five acaricide concentrations: 180 mg/l (maximum recommended concentration for use in glasshouses against spider mites), 18 mg/l, 1.8 mg/l and 0.18 mg/l (the last one was discriminative for eggs and immatures in preliminary studies, i.e. produced 100% mortality of those stages) and 0.018 mg/l. After 24h exposure, the percentages of females surviving treatment without visible symptoms of poisoning were 50% (180 mg/l), 45% (18 mg/l), 51% (1.8 mg/l), 74% (0.18 mg/l), 96% (0.018 mg/l) and 98% (0 mg/l). Over the first four days after treatment, the females that survived 180 mg/l and 18 mg/l laid no eggs. The total number of eggs laid after treatment with these two concentrations was reduced to less than 2% against the control by the end of the trial. The females that survived 1.8 mg/l laid 50% less eggs, compared to the control, while the number of eggs laid by the females treated with 0.18 mg/l and 0.018 mg/l were 19% and 4% lower, respectively. Over the initial four days, egg hatch rates in treatments were 73-87%, and 92-93% in the control. Significant statistical differences between gross fecundity (FCg) and gross fertility (FTg) values in the control and treatments were detected for females surviving 180 mg/l, 18 mg/l and 1.8 mg/l. On the other hand, only the net fertility (FTn) value of females treated with 0.018 mg/l showed no statistically significant difference from the control value. Treatments with 180 mg/l and 18 mg/l significantly reduced the instantaneous rate of increase (r i ) 6, 8 and 10 days after treatment, compared to the control. The negative r i values in those treatments indicated a declining population. Sublethal effects of spiromesifen and its impact on T. urticae management are discussed.